Intellia Therapeutics, Inc.

Jacob Rubens was supposed to be paying attention in his chemistry lecture. Instead, flipping through Rolling Stone, he stumbled upon an interview that would alter the trajectory of his life. “I was re

News that US Food and Drug Administration Center for Biologics Evaluation and Research (CBER) director Peter Marks submitted his resignation, effective 5 April, late in the day on 28 March shook the b

Third Harmonic Bio and Q32 Bio are not in imminent danger of running out of cash, but both companies recently took a look at early data for their lead drug candidates and decided to significantly cut

January’s J.P. Morgan Healthcare Conference should set the tempo for biotech and pharma companies over the year as mergers and acquisitions along with early announcements of full-year 2024 financials